Receptor for advanced glycation end products (RAGE) and its inflammatory ligand EN-RAGE in non-diabetic subjects with pre-mature coronary artery disease

Atherosclerosis

Volumn 207, Issue 2, 2009, Pages 597-602

  Mahajan, Nitin ^a   Malik, Namita ^a   Bahl, Ajay ^a   Dhawan, Veena ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

CAD; EN RAGE; Gensini score; PBMCs; RAGE; sRAGE

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; BINDING PROTEIN; C REACTIVE PROTEIN; EXTRACELLULAR NEWLY IDENTIFIED ADVANCED GLYCATION END PRODUCT RECEPTOR BINDING PROTEIN; MESSENGER RNA; UNCLASSIFIED DRUG;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY RISK; DISEASE SEVERITY; FEMALE; GENE EXPRESSION; GENSINI SCORE; HUMAN; HUMAN CELL; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; PATHOPHYSIOLOGY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCORING SYSTEM;

ADULT; AGE OF ONSET; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; INFLAMMATION MEDIATORS; LIGANDS; LOGISTIC MODELS; MALE; MIDDLE AGED; RECEPTORS, IMMUNOLOGIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK ASSESSMENT; RISK FACTORS; RNA, MESSENGER; S100 PROTEINS; SEVERITY OF ILLNESS INDEX; TRANSCRIPTIONAL ACTIVATION; UP-REGULATION; YOUNG ADULT;

EID: 70450228643     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2009.06.003     Document Type: Article

References (44)

1. Ramaraj R., and Alpert J.S. Indian poverty and cardiovascular disease. Am J Cardiol 102 (2008) 102-106
2. Pahlajani D.B., and Chawal M.H. Coronary artery disease pattern in ice young. JAPI 37 (1989) 312-315
3. Hofmann M.A., Drury S., Fu C., et al. RAGE mediates a novel pro-inflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 97 (1999) 889-901
4. Foell D., Ichida F., Vogl T., et al. S100A12 (EN-RAGE) in monitoring Kawasaki disease. Lancet 61 (2003) 1270-1272
5. Foell D., Kane D., Bresnihan B., et al. Expression of the pro-inflammatory protein S100A12 (EN-RAGE) in rheumatoid and psoriatic arthritis. Rheumatology 42 (2003) 1383-1389
6. Foell D., Kucharzik T., Kraft M., et al. Neutrophil derived human S100A12 (EN-RAGE) is strongly expressed during chronic active inflammatory bowel disease. Gut 52 (2003) 847-853
7. Basta G. Receptor for advanced glycation end products and atherosclerosis: from basic mechanisms to clinical implications. Atherosclerosis 196 (2008) 9-21
8. Geroldi D., Falcone C., and Emanuele E. Soluble receptor for advanced glycation end products: from disease marker to potential therapeutic target. Curr Med Chem 13 (2006) 1971-1978
9. Geroldi D., Falconea C., Emanuele E., et al. Decreased plasma levels of soluble receptor for advanced glycation end-products in patients with essential hypertension. J Hypertens 23 (2005) 1725-1729
10. Emanuele E., D'Angelo A., Tomaino C., et al. Circulating levels of soluble receptor for advanced glycation end products in Alzheimer disease and vascular dementia. Arch Neurol 62 (2005) 1734-1736
11. Ghidoni R., Benussi L., Glionna M., et al. Decreased plasma levels of soluble receptor for advanced glycation end products in mild cognitive impairment. J Neural Transm 115 (2008) 1047-1050
12. Falcone C., Emanuele E., D'Angelo A., et al. Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men. Arterioscler Thromb Vasc Biol 25 (2005) 1032-1037
13. Katakami N., Matsuhisa M., Kaneto H., et al. Decreased endogenous secretory advanced glycation end product receptor in type 1 diabetic patients: its possible association with diabetic vascular complications. Diabetes Care 28 (2005) 2716-2721
14. Koyama H., Shoji T., Yokoyama H., et al. Plasma level of endogenous secretary RAGE is associated with components of the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol 25 (2005) 2587-2593
15. Choi K.M., Yoo H.J., Kim H.Y., et al. Association between endogenous secretory RAGE, inflammatory markers and arterial stiffness. Int J Cardiol 132 (2009) 96-101
16. Pietzsch J., and Hoppmann S. Human S100A12: a novel key player in inflammation?. Amino Acids 36 (2009) 381-389
17. Pearson T.A., Mensah G.A., Alexander R.W., et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107 (2003) 499-511
18. JNC-VI. The sixth report of Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure. Arch Intern Med 157 (1997) 2413-2446
19. Enas E.A. Lipoprotein(a) is an important genetic risk factor for pre-mature coronary artery disease in Asian Indians. Am J Cardiol 88 (2001) 201-202
20. Sharma M., and Ganguly N.K. Pre-mature coronary artery disease in Indians and its associated risk factors. Vasc Health Risk Manage I (2005) 217-225
21. World medical association declaration of Helsiniki. Cardiovasc Res 35 (1997) 2-3
22. Gensini G.G. A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol 51 (1983) 606-607
23. Friedwald W.T., Levy R.I., and Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 18 (1972) 499-502
24. Boyum A. Separation of Leucocytes from blood and bone marrow. Scand J Clic Lab Invest 21 (1968) 77
25. Mahajan N, Bahl A, Dhawan V. C-reactive protein (CRP) up-regulates the expression of receptor for advanced glycation end products (RAGE) and its inflammatory ligand EN-RAGE in THP-1 cells: inhibitory effects of atorvastatin. Int J Cardiol. doi:10.1016/j.ijcard.2009.01.008.
26. Haidari M., Javadi E., Sadeghi B., Hajilooi M., and Ghanbili J. Evaluation of C-reactive protein, a sensitive marker of inflammation, as a risk factor for stable coronary artery disease. Clin Biochem 33 (2001) 309-315
27. Tataru M.C., Heinrich J., Junker R., et al. C-reactive protein and the severity of atherosclerosis in myocardial infarction patients with stable angina pectoris. Eur Heart J 21 (2000) 1000-1008 [see comments]
28. Rifai N., Joubran R., Yu H., Asmi M., and Jouma M. Inflammatory markers in men with angiographically documented coronary heart disease. Clin Chem 45 (1999) 1967-1973
29. Abdelmouttaleb I., Danchin N., Ilardo C., et al. C-Reactive protein and coronary artery disease: additional evidence of the implication of an inflammatory process in acute coronary syndromes. Am Heart J 137 (1999) 346-351 [see comments]
30. Mendall M.A., Strachan D.P., Butland B.K., et al. C-reactive protein: relation to total mortality, cardiovascular mortality and cardiovascular risk factors in men. Eur Heart J 21 (2000) 1584-1590
31. Tracy R.P., Psaty B.M., Macy E., et al. Lifetime smoking exposure affects the association of C-reactive protein with cardiovascular disease risk factors and subclinical disease in healthy elderly subjects. Arterioscler Thromb Vasc Biol 17 (1997) 2167-2176
32. Santilli F., Bucciarelli L., Noto D., et al. Decreased plasma soluble RAGE in patients with hypercholesterolemia: effects of statins. Free Radic Biol Med 43 (2007) 1255-1262
33. Burke A.P., Kolodgie F.D., Zieske A., et al. Morphologic findings of coronary atherosclerotic plaques in diabetics. A postmortem study. Arterioscler Thromb Vasc Biol 24 (2004) 1266-1271
34. Schmidt A.M., and Yan S.D. Stern DM: the dark side of glucose. Nat Med 1995 (2001) 1002-1004
35. Hou F.F., Reddan D.N., Seng W.K., et al. Pathogenesis of β2-microglobulin amyloidosis: role of monocytes/macrophages. Semin Dial 14 (2001) 135-139
36. Hou F.F., Jiang J.P., Guo J.Q., et al. Receptor for advanced glycation end products on human synovial fibroblasts: role in the pathogenesis of dialysis-related amyloidosis. J Am Soc Nephrol 13 (2002) 1296-1306
37. Yang Z., Tao T., Raftery M.J., et al. Inflammatory properties of the human S100 protein S100A12. J Leukoc Biol 69 (2001) 986-994
38. Park I.H., Yeon S.I., Youn J.H., et al. Expression of a novel secreted splice variant of the RAGE in human brain astrocytes and peripheral blood mononuclear cells. Mol Immunol 40 (2004) 1203-1211
39. Raucci A., Cugusi S., Antonelli A., et al. A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10). FASEB J 22 (2008) 3716-3727
40. Zhang L., Bukulin M., Kojro E., et al. Receptor for advanced glycation end products is subjected to protein ectodomain shedding by metalloproteinases. J Biol Chem 283 (2008) 35507-35516
41. Hudson B.I., Carter A.M., Harja E., et al. Identification, classification, and expression of RAGE gene splice variants. FASEB J (2008) doi:10.1096/fj.07-9909
42. Yonekura H., Yamamoto Y., Sakurai S., et al. Novel splice variants of the RAGE expresses in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J 370 (2003) 1097-1109
43. Cipollone F., Iezzi A., Fazia M., et al. The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques. Role of glycemic control. Circulation 108 (2003) 1070-1077
44. Cuccurullo C., Iezzi A., Fazai M.L., et al. Suppression of RAGE as a basis of simvastatin-dependent plaque destabilization in type 2 diabetes. Arterioscler Thromb Vasc Biol 26 (2006) 2716-2723